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Background: There are some animal studies suggesting the possible role of vitamin C for treating depression.
However, the efficacy of vitamin C for treating adult patients with major depressive disorder (MDD) has never been
examined.
Methods: This 8-week randomized double-blind placebo-controlled clinical trial included adult patients with major
depressive disorder according to DSM-IV diagnostic criteria. Twenty-one patients in the treatment group received
citalopram plus vitamin C and the 22 patients in the control group received citalopram plus placebo. The Hamilton
Depression Rating Scale was used to measure depressive symptoms at baseline, week 2, week 4, and week 8. We
also checked for the presence of adverse effects.
Results: While depression symptoms decreased in both groups during this trial, there was no statistically significant
difference between the 2 groups (P = .5). The rate of remission, partial response, and complete response was not
different between the two groups. The rate of adverse effects were not different between the two groups.
Conclusion: Adding vitamin C to citalopram did not increase the efficacy of citalopram in MDD patients. Vitamin C
plus citalopram is as effective as placebo plus citalopram for treating adult patients with suicidal behavior. No serious
adverse effect for this combination was identified during this trial.
Trial registration: This trial was registered at http://www.irct.ir. The registration number of this trial was:
IRCT201312263930N31. Date registered: 5 July 2014.
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Current literature suggests the possible role of oxidative
stress in the pathophysiology of major depressive disorder
(MDD). While the plasma ascorbic acid level is decreased
in MDD, the serum levels of superoxide dismutase (SOD)
and serum malondialdehyde (MDA) as two markers of
oxidation are increased [1]. Ascorbic acid prevents stress-
induced cerebrocortical and hippocampal lipid peroxida-
tion and SOD activity in mice [2]. In addition, ascorbic
acid inhibits the increment of the two oxidative stress* Correspondence: ghanizadeha@hotmail.com
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unless otherwise stated.markers of glutathione reductase and glutathione peroxid-
ase activities in a preclinical model [2]. However, a ran-
domized, double-blind, placebo-controlled study failed to
show the expected beneficial effects of vitamin C on
oxidative stress in humans [3]. Clinical studies do not
support that vitamin C changes the markers of oxida-
tion in humans [4].
The water-soluble vitamin C or ascorbic acid is one of
the most important antioxidants in humans [5]. Vitamin C
is a part of the intracellular antioxidant system with neuro-
protective effects [6].
Antidepressants are capable of reversing the changes
in oxidative stress parameters in MDD patients [7,8]. A
clinical trial demonstrated that the peripheral activity of
the antioxidant enzyme SOD and the levels of the oxida-
tive marker MDA were higher in MDD patients [1]. Thesel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ascorbic acid and reverted after treatment with fluoxetine
and citalopram, further reinforcing the role of ascorbic
acid in MDD [1]. In addition, ascorbic acid had an effect
similar to fluoxetine in an animal model of depression,
reverting not only the behavioral profile induced by stress
but also the oxidative damage [8].
There are some promising reports about the benefi-
cial effect of vitamin C in animal models of depression.
‘Nevertheless, supplementary vitamins C did not decrease
depression in type 2 diabetic patients in a randomized,
single-blind, placebo-controlled trial’ [9].
Ascorbic acid has antidepressant-like effects in animals
[8]. In addition, vitamin C potentiated the antidepressant
effects of antidepressants in animals [10]. Ascorbic acid
produces an antidepressant-like effect by interaction
with the monoaminergic system in animal models [10].
In addition, antagonists of glutamatergic N-methyl-D-
aspartate (NMDA) receptors rapidly decrease depressive
symptoms [11]. Additionally, vitamin C has some anti-
NMDA effects [10,12].
The results of the effects of vitamin C on depression
in healthy individuals and patients with some medical
conditions are contradictory. A randomized double-blind,
placebo-controlled 14-day trial of sustained-release ascor-
bic acid including 42 healthy young adults showed that
vitamin C (3,000 mg/day) increased mood measured by
the Beck Depression Scale [13]. Vitamin C also decreased
psychological subjective stress [14]. In a randomized
double-blind placebo-controlled trial including depressed
shift workers, vitamin C (500 mg/day) significantly de-
creased depression severity. The 21-item Beck Depression
Rating Scale score decreased from 14.133 ± 4.37 to 3.233 ±
7.08 (P < 0.018) [15]. Nevertheless, supplementary vitamin C
(1,000 mg/day) did not decrease the depression score
in type 2 diabetic patients in a randomized, single-blind,
placebo-controlled trial [9].
Non-controlled and limited evidence from clinical studies
supports the efficacy of vitamin C for treating depressive
disorder. For example, vitamin C relieved adrenocorticotro-
pic hormone-induced depressive symptoms in a patient
during a 14-day period [16]. The levels of vitamins A, C,
and E in patients with depression are lower than that of the
healthy controls [17]. Adding the combination of 600 mg/
day of vitamin A, 1,000 mg/day of vitamin C, and 800 mg/
day of vitamin E to escitalopram (10 to 20 mg/day) im-
proved depression [17]. Nevertheless, another study re-
ported that depression is not associated with vitamin C
level [18]. The only published clinical trial that examined
the efficacy of vitamin C as an adjuvant agent for treating
MDD included pediatric patients. There were 12 pa-
tients in the fluoxetine (10 to 20 mg/day) plus vitamin C
(1,000 mg/day) group. The control group included 12 pa-
tients administered fluoxetine (10 to 20 mg/day) plusplacebo. Depression score decreased in the treatment
group more than that of the control group during
3 months as measured by the Children’s Depression
Rating Scale (CDRS) [19]. However, the scale of Clinical
Global Impression (CGI) did not show the efficacy of vita-
min C for treating patients with MDD in the same trial
[19]. Furthermore, suicidal behavior is common in pa-
tients with MDD and oxidative stress and lower total anti-
oxidant levels are associated with a history of suicidal
attempts [19].
Considering the preliminary reports from animal stud-
ies, a case report about the efficacy of vitamin C [16],
the contradictory results of one clinical trial on adoles-
cents with depression [19], and the role of oxidative
stress in MDD and suicidal behavior, well-controlled trials
are needed to examine whether the effect of vitamin C as
an adjuvant medication improves MDD in adults. To the
best of the authors’ knowledge, this matter has never been
examined in adult patients with MDD. Therefore, we con-
ducted a randomized double-blind placebo-controlled
clinical trial to examine the efficacy and safety of vitamin
C for treating MDD and suicidal behavior. We hypothe-
sized that vitamin C would augment the antidepressant ef-
fects of citalopram in treating adult patients with MDD.
Methods
The study was performed in accordance with the Declar-
ation of Helsinki (1964). This trial was approved by the
Ethics Committee of Shiraz University of Medical Sciences
(number: CT-P-92-6070). The participants were provided
with information about the trial procedure, risks, and
benefits. Then, the participants provided their written
informed consent. This trial is registered in the IRCT
(IRCT201312263930N31). This trial was performed at
the Department of Psychiatry at Shiraz University of
Medical Sciences from September 2013 to March 2014.
Participants
This is a randomized controlled clinical trial investigating
the effectiveness of vitamin C in addition to citalopram
for treating MDD. Participants were 60 adult outpatients
who met the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) criteria for MDD.
Diagnosis was made through a clinical interview by a
board-certified psychiatrist. There were two groups. One
group received citalopram (up to 60 mg/day) plus
vitamin C (up to 1,000 mg/day). The other group received
citalopram plus placebo. Citalopram was started with
10 mg/day and increased to 20 mg/day over 7 days. The
dosage could be adjusted according to adverse effects. No
other antidepressant medication or psychotherapy was
administered during this trial. The patients and/or care-
givers were asked whether they took the medications in
order to check the patients’ medication compliance.
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tablets were made by the Faculty of Shiraz University
of Medical Sciences. The patients, the rater, and the
clinician who referred the patients were blind to the group
allocation.
The inclusion criteria were: a score of 16 or higher on
the Hamilton Depression Rating Scale (HDRS); no psy-
chotropic medication for at least 4 weeks; untreated pa-
tients; both genders; and aged more than 18 years and
no more than 65 years old.
The exclusion criteria were: 1) significant co-morbid
psychiatric illness, hypothyroidism or severe medical
conditions such as epilepsy; 2) psychotic features or bi-
polar mood disorder or any other psychiatric disorder;
current substance abuse except cigarette smoking; sui-
cidal attempt; oral contraception use; pregnancy; breast-
feeding; intention to become pregnant during this trial; a
history of allergic reactions to vitamin C or citalopram;
and receiving psychotropic medication. Suicidal ideation
was not an exclusion criterion.
Outcomes
The patients were assessed 4 times including at baseline,
week 2, week 4, and week 8. The HDRS-21 was the pri-
mary outcome measure to assess depression severity [20].
The item 3 was scored to measure suicidal behavior. Mean
difference of HDRS was compared between the two
groups. Reduction of more than 49% in score from base-
line to week 8 was defined as response [21]. The 2 groups
were compared regarding complete response (# 50%),
partial response (# 25% decline in HDRS score), and the
rate of adverse effects. The rate of full remission (HDRS
less than 8) was compared between the 2 groups [22]. The
secondary outcome measure was the Beck Depression
Inventory (BDI).
Adverse effects
A checklist was used to check adverse effects. In addition,
the patients and caregivers were requested to report any
adverse effects. They were provided with a phone number
to contact us whenever any adverse effect or any question
about the trial arose.
The procedure
The order of entrance in the trial was used for randomization.
A random number generator provided a list. The rater
and the man who randomized the patients into the groups
were two different persons.
Sample size
A published clinical trial showed that adding vitamin C to
fluoxetine therapy in 12 children with MDD decreased the
CDRS score. This scale is derived from the HDRS. The
score decreased from 30.1 ± 3.56 to 14.4 ± 2.39. Meanwhile,the score in the placebo group decreased from 31.3 ± 3.89
to 24.7 ± 2.73 [19]. To determine the sample size, the re-
sult of the previous study was used [19]. A total of eight
patients are needed to enter this two-treatment parallel-
design study. The probability is 98% that the study will
detect a treatment difference (P-value < 0.05 at a 2-sided,
df = 9.0, SD = 2.5).
Statistical analysis
SPSS software (Chicago, IL, USA) was used to run the
statistical analysis. Continuous variables were compared
between the two groups using two-sample t-tests to
examine differences in means. Repeated measures ana-
lysis of variance (ANOVA) was used to compare the
scores between the two groups. Group was considered
as a between subjects factor and the four measurements
during trial (time) were considered as a within subject
factor. Repose rates, remission rate, and categorical vari-
ables were compared between the two groups using Chi
square test or Fisher’s exact test. The last observation
carried forward method was used for handling missing
data. The patients who were assessed at least twice were
analyzed. A P -value less than 0.05 was set as significant
level.
Results
The flow of patients in the trial is displayed in Figure 1.
Seventy-eight patients were screened to enter this trial.
Ten patients were excluded because the severity of de-
pression according to HDRS was not severe enough. From
the 68 patients who were randomly allocated into one of
the two groups, 35 patients were in the placebo group and
33 patents were allocated into the vitamin C group.
Twelve patients in the vitamin C group and 13 patients in
the placebo group declined to participate. From 22 pa-
tients in the vitamin C group, 1 patient dropped out due
to lack of efficacy of the intervention. Two patients in the
placebo group dropped out because the intervention was
ineffective. All 43 patients who did not decline to partici-
pate had at least 1 follow-up assessment. In all, 40 patients
completed this trial. These 43 patients were included in
this intent-to-treat analysis.
The mean age of the patients who declined to partici-
pate in this trial was not different from those who partici-
pated (31.0 (9.6) versus 33.5 (9.4) years old, respectively;
t = 1.02, df = 65, P = .3). Moreover, the HDRS score at
baseline was not different between the patients who de-
clined to participate and those who participated (23.2 (4.9)
versus 22.2 (3.2); respectively; t = 1.06, df = 66, P = .2).
In addition, their gender ratio was not different (X2 = .8,
df = 1, P = .3).
The rate of females in the vitamin C and placebo groups
was 15 (71.4%) and 17 (77.2%), respectively (X2 = .19, df = 1,
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Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart of the patients in this trial.
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and placebo group was 32.7 (8.4) and 34.2 (10.3) years old.
There was no statistically significant difference between
the 2 groups regarding the mean of age (t = 1.5, df = 41,
P = .5).
None of the patients had any psychotic features (Table 1).
None of the patients had a positive history of being
administered electroconvulsive therapy. Body Mass Index
of the patients and the mean dosage of citalopram were
not different between the two groups.
Efficacy
The mean (SD) scores of HDRS are displayed in Table 1.
The HDRS score was not different between the two
groups at baseline. Repeated measure of ANOVA showed
that the HDRS score significantly decreased during thistrial in both groups (F(3,120) = 154.6, P < 0.001) (Figure 2).
However, the interaction of time and group (time × group)
was not statistically different (F(3,120) = .57, P = .6). In
other words, the behavior of the two treatments was simi-
lar across time. In addition, repeated measure ANOVA
showed that there was no statistical difference between
the 2 groups (F(1,40) = .33, P = .5). Additionally, the differ-
ence between the 2 groups was similar at the endpoint
(t = −.3, df = 41, P = .6).
The percent of decline of HDRS in the vitamin C
and placebo groups was 60.0% and 59.2%, respectively
(t = −.1, df = 41, P = .9).
Remission rate
The rate of remission was not different between the 2 groups
(7 (35.0%) versus 8 (36.4%); X2 = 0.008, df = 1, P = .4).
Table 1 The characteristics of the patients and depression score and its changes in the groups
Vitamin C group (n = 21) Placebo group (n = 22)
Mean (SD) years of age 32.7 (8.4) 34.2 (10.3) t = 1.5, df = 41, P = .5
Number (%) of females 15 (71.4) 17 (77.2%) X2 = .19, df = 1, P = .6
Marital status n (%) Single 7 (31.9%) 7 (31.8%) X2 = .1, df = 2, P = .9
Married 13 (59.1%) 14 (63.6%)
Divorced 1 (4.5%) 1 (4.5%)
Psychotic features 0 0 -
Number (%) of smokers 2 (9.1%) 2 (9.1%) -
Positive history of being administered ECT 0 0 -
Mean (SD) of Body Mass Index 25.1 (3.4) 26.3 (6.5) t = .7, df = 42, P = .4
Citalopram mean (SD) dosage (mg/day) During first 2 weeks 20.2 (0.) 20.9 (4.2) t = −1.0, df = 42, P = .3
During weeks 3 and 4 24.0 (6.6) 24.5 (7.3) t = −.2, df = 42, P = .8
During second month 35.0 (7.4) 33.5 (7.4) t = −.6, df = 40, P = .5
Hamilton Depression Rating Scale score Baseline 21.4 (4.1) 22.4 (3.0) t = −.9, df = 42, P = .3
Week 2 15.0 (5.6) 16.9 (6.0) t = 1.0, df = 42, P = .4
Week 4 11.2 (6.8) 11.9 (5.9) t = −.3, df = 41, P = .7
Week 8 8.6 (5.2) 9.3 (6.3) t = −.3, df = 41, P = .6
Decline of Hamilton Depression Rating Scale score (%) 60.0 (20.3 59.2 (26.9) t = −.1, df = 41, P = .9
Mean (SD) of Beck Depression Inventory score Baseline 23.9 (8.3) 22.8 (9.8) t = −.3, df = 41, P = .6
Week 2 18.0 (11.1) 17.9 (9.8) t = .02, df = 41, P = .9
Week 4 14.8 (10.8) 15.1 (10.4) t = .1, df = 41, P = .9
Week 8 8.6 (10.7) 9.0 (9.6) t = −.1, df = 41, P = .9
Mean (SD) decline of suicidal score 1.0 (0.9) 0.9 (0.9) t = −.3, df = 37, P = .7
Abbreviation: ECT electroconvulsive therapy.
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Sixteen (48.5%) of the patients in the vitamin C group and
17 (51.5%) of the patients in the placebo group showed a
complete response (X2 = 0.04, df = 1, P = .8).
Partial response rate
The rate of partial response was not different between
the two groups (20 (100.0%) versus 19 (86.4%); X2 = 2.9,
df = 1, P = .08).
Suicidal behavior
The mean score of suicidal behavior in the vitamin C and
placebo groups at baseline was 1.7 (1.4) and 1.7 (1.3), re-
spectively. It was not different between the two groups
(t = −.02, df = 41, P = .9). The suicidal score decline in
the vitamin C and placebo group was 1.0 (0.9) and
0.9 (0.9), respectively.
Beck Depression Inventory
The mean (SD) score of the BDI was not different
between the two groups at baseline (Table 1). The BDI
score decreased from 23.9 (8.3) to 8.6 (10.7) in the
vitamin C group. The score decreased from 22.8 (9.8) to
9.0 (9.6) in the placebo group.Clinical adverse effects
There was no serious adverse effect. Nobody dropped
out due to an adverse effect. Three patients stopped the
interventions because it was ineffective.
None of the adverse effects were so severe to necessi-
tate a change of intervention protocol. The adverse effects
were transient and resolved spontaneously. The most
common adverse effects in both groups were nausea, dry
mouth, pain, sweating, and decreased appetite. Table 2
shows that the rates of adverse effects were not different
between the two groups.
Discussion
The results of this randomized double-blind placebo-
controlled clinical trial indicate that the administration
of vitamin C as an adjuvant medication with citalopram
did not increase the efficacy of citalopram for treating
depressive symptoms in patients with MDD. The rates
of partial response, complete response, and remission
were not different between the two groups. Vitamin C
as much as placebo decreased depression symptoms.
These findings are not in line with the results reported
from animal studies [8,12,23,24]. Nevertheless, this is the
first randomized controlled clinical trial examining the
Figure 2 The mean change of Hamilton Depression Rating Scale in the groups during the trials.
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patients with MDD. It should be noted that there is a
difference between animal studies and major depression
in humans. The animal studies measured depression
induced by stress. It is clear that the stress-induced
response is not equal to MDD.
The only trial conducted in humans reported contra-
dictory results about the effectiveness of vitamin C for
treating depression symptoms in adolescents [19]. That
trial reported that vitamin C did not decrease depression
symptoms measured by the CGI scale. However, the
depression symptoms were measured by the CDRS [19].
In addition, the other trial which showed the efficacy of
vitamin C had been conducted on healthy individuals
[13] rather than patients with MDD.
Considering that oxidative stress is associated with
depression [25], it was expected that vitamin C would
decrease depression symptoms and suicidal behavior.
Individuals with depression markedly intake dietary anti-
oxidants less than those without depression [26]. Vitamin
C has a protective role for oxidative status in stress [2]. Inaddition, some anti-inflammatory agents such as celecoxib
effectively decrease inflammatory markers and depression
symptoms in patients with MDD [27,28]. Nevertheless,
our results failed to support this assumption. This is in
line with a study that vitamin C level was not associated
with depression symptoms in community-based adults
[29]. Another explanation is that although MDD is as-
sociated with oxidative stress the effect of antidepressants
is independent of oxidative and antioxidative stress sys-
tems [25].
The ceiling effect may be another explanation for the
negative results of this trial. It means that citalopram has
masked the potential benefit of vitamin C. The animal
studies did not concurrently administered citalopram. To
eliminate the ceiling effect, a monotherapy trial of vitamin
C compared to placebo is needed.
Suicidal behavior and serotonin-specific reuptake inhibitor-
related emergent suicidal ideation and behavior are a mat-
ter of clinician’s concern in treating patients with MDD.
However, efficacy results for this trial showed that vitamin
C was not statistically different from placebo for treating
Table 2 The rate of adverse effects by group




Nausea 12 (57.1) 11 (52.4) X2 = 0.09, df = 1, P = .7
Fatigue 9 (42.8) 8 (38.1) X2 = 0.09, df = 1, P = .5
Dry mouth 7 (33.3) 9 (42.9) X2 = 0.4, df = 1, P = .5
Pain 6 (28.6) 8 (38.1) X2 = 0.4, df = 1, P = .5
Sweating 0 4 -
Decreased
appetite
4 (19) 6 (28.6) -
Abdominal pain 3 (14.3) 3 (14.3) -
Increased appetite 3 (14.3) 0 (0.0) -
Restlessness 3 (14.3) 2 (9.5) -
Insomnia 3 (14.3) 1 (4.8) -
Blurred vision 0 3 (14.3) -
Itch 0 2 (9.5) -
Tremor 0 2 (9.5) -
Dizziness 1 (4.8) 2 (9.5) -
Daytime
drowsiness
2 (9.5) 0 -
Drooling 1 (4.8) 0 (0.0) -
Nervousness 1 (4.8) 1 (4.8) -
Constipation 0 1 (4.8) -
Lethargy 0 1 (4.8) -
Tachycardia 0 1 (4.8) -
Dystonia 0 0 -
Diarrhea 0 1 (4.8) -
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verse effects, the rates of adverse effects were not different
between the two groups.
While no double-blind randomized controlled clinical
trial has ever examined the effect of vitamin C for treat-
ing depression symptoms in adults patients with MDD,
the small sample size, short duration, and fixed dose of
vitamin C were among the limitations of this trial. The
current trial included patients without psychosis. It is
not clear whether vitamin C is effective for treating pa-
tients with severe forms of MDD or those with psychotic
features. Although some studies have reported that the
level of vitamin C is not associated with depression symp-
toms, the current trial did not control the dietary intake
of vitamin C. Moreover, it is possible that the dose of
vitamin C was insufficient. Although none of the patients
in the current trial were psychotic and the severity of
depression at baseline was not different between the two
groups, future studies should consider duration and age of
onset of depression as possible co-variate factors. Finally,
25 out of 68 patients declined to participate in this trial;
they may be a source of potential bias.Conclusion
Treating MDD with vitamin C adds nothing to the short-
term efficacy of citalopram. This combination is not effective
regarding suicidal behavior. However, this combination seems
to be safe and well-tolerated.
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